1. Home
  2. ESPR
  3. ESPR News

Latest Esperion Therapeutics Inc. (ESPR) News on November 26, 2025

Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
ESPR

GlobeNewswire

7 days ago

Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference

HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
ESPR

CNW Group

8 days ago

HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
ESPR

GlobeNewswire

8 days ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR

GlobeNewswire

19 days ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
ESPR

GuruFocus.com

19 days ago

Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
ESPR

Zacks

20 days ago

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

ESPR

Associated Press Finance

20 days ago

Esperion Therapeutics: Q3 Earnings Snapshot

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
ESPR

GlobeNewswire

20 days ago

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
ESPR

GlobeNewswire

22 days ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Esperion to Participate in Jefferies Global Healthcare Conference - London
ESPR

GlobeNewswire

23 days ago

Esperion to Participate in Jefferies Global Healthcare Conference - London

Esperion to Report Third Quarter 2025 Financial Results on November 6
ESPR

GlobeNewswire

a month ago

Esperion to Report Third Quarter 2025 Financial Results on November 6

CREATING POSITIVE IMPACT IN SUSTAINABILITY
ESPR

GlobeNewswire

a month ago

CREATING POSITIVE IMPACT IN SUSTAINABILITY

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
ESPR

Zacks

a month ago

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up

Esperion Therapeutics (ESPR): Assessing Valuation After $75 Million Discounted Stock Offering and Share Price Drop
ESPR

Simply Wall St.

a month ago

Esperion Therapeutics (ESPR): Assessing Valuation After $75 Million Discounted Stock Offering and Share Price Drop

Why Esperion Therapeutics (ESPR) Is Up After $75M Equity Raise and Generic Settlement News
ESPR

Simply Wall St.

2 months ago

Why Esperion Therapeutics (ESPR) Is Up After $75M Equity Raise and Generic Settlement News

ESPR- Japanese Drug Approval, Otsuka Payments to Help this Biotech Play
ESPR

MoneyShow

2 months ago

ESPR- Japanese Drug Approval, Otsuka Payments to Help this Biotech Play

ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering
ESPR

Zacks

2 months ago

ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?
ESPR

Zacks

6 months ago

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
ESPR

GlobeNewswire

6 months ago

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

Esperion to Participate in Upcoming June Investor Conferences
ESPR

GlobeNewswire

6 months ago

Esperion to Participate in Upcoming June Investor Conferences

ESPR

MT Newswires

6 months ago

Esperion Therapeutics, Micro Labs Settle Generic Nexletol Patent Dispute

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
ESPR

GlobeNewswire

6 months ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
ESPR

Pharmaceutical Technology

7 months ago

HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
ESPR

GlobeNewswire

7 months ago

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR

GlobeNewswire

7 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

HLS Therapeutics Announces Q1 2025 Financial Results
ESPR

CNW Group

7 months ago

HLS Therapeutics Announces Q1 2025 Financial Results

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
ESPR

GlobeNewswire

7 months ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada
ESPR

CNW Group

7 months ago

HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
ESPR

Zacks

7 months ago

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

Esperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
ESPR

GuruFocus.com

7 months ago

Esperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...

Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
ESPR

Zacks

7 months ago

Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

ESPR

Associated Press Finance

7 months ago

Esperion Therapeutics: Q1 Earnings Snapshot

Esperion Reports First Quarter 2025 Financial Results
ESPR

GlobeNewswire

7 months ago

Esperion Reports First Quarter 2025 Financial Results

Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?
ESPR

Zacks

7 months ago

Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
ESPR

Zacks

7 months ago

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion to Participate in The Citizens Life Sciences Conference
ESPR

GlobeNewswire

7 months ago

Esperion to Participate in The Citizens Life Sciences Conference

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
ESPR

Zacks

7 months ago

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
ESPR

GlobeNewswire

7 months ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
ESPR

Zacks

7 months ago

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Esperion to Report First Quarter 2025 Financial Results on May 6
ESPR

GlobeNewswire

7 months ago

Esperion to Report First Quarter 2025 Financial Results on May 6

Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ESPR

Zacks

7 months ago

Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

ESPR

Argus Research

7 months ago

Daily – Vickers Top Buyers & Sellers for 04/22/2025

Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
ESPR

GuruFocus.com

7 months ago

Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
ESPR

GlobeNewswire

8 months ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?
ESPR

Zacks

8 months ago

Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?

Esperion Appoints Robert E. Hoffman to Board of Directors
ESPR

GlobeNewswire

8 months ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference
ESPR

GlobeNewswire

8 months ago

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
ESPR

Zacks

8 months ago

ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia

ESPR

MT Newswires

8 months ago

Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
ESPR

GlobeNewswire

8 months ago

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
ESPR

Zacks

9 months ago

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

ESPR

Thomson Reuters StreetEvents

9 months ago

Q4 2024 Esperion Therapeutics Inc Earnings Call

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
ESPR

Zacks

9 months ago

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

ESPR

Associated Press Finance

9 months ago

Esperion Therapeutics: Q4 Earnings Snapshot

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
ESPR

GlobeNewswire

9 months ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
ESPR

GlobeNewswire

9 months ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?
ESPR

Insider Monkey

9 months ago

Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
ESPR

Zacks

9 months ago

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know
ESPR

Zacks

9 months ago

Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
ESPR

GlobeNewswire

9 months ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR

GlobeNewswire

9 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
ESPR

Zacks

10 months ago

Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
ESPR

GlobeNewswire

a year ago

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
ESPR

GlobeNewswire

a year ago

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

ESPR

MT Newswires

a year ago

Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
ESPR

GlobeNewswire

a year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

ESPR

MT Newswires

a year ago

Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target

ESPR

MT Newswires

a year ago

Esperion Swaps New Notes, Cash for $210 Million of Convertible Debt; Shares Slump Pre-Bell

Esperion Announces $210 Million Convertible Debt Financing
ESPR

GlobeNewswire

a year ago

Esperion Announces $210 Million Convertible Debt Financing

ESPR

MT Newswires

a year ago

Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
ESPR

GlobeNewswire

a year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
ESPR

Zacks

a year ago

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

ESPR

MT Newswires

a year ago

Esperion Therapeutics Files Applications for Non-Statin Medications in Canada

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
ESPR

GlobeNewswire

a year ago

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

ESPR

MT Newswires

a year ago

Esperion Therapeutics' Bempedoic Acid Submitted for Approval in Japan by Otsuka Pharmaceutical

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
ESPR

GlobeNewswire

a year ago

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
ESPR

GlobeNewswire

a year ago

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
ESPR

GlobeNewswire

a year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR

GlobeNewswire

a year ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
ESPR

GuruFocus.com

a year ago

Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
ESPR

Zacks

a year ago

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
ESPR

Zacks

a year ago

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

ESPR

Associated Press Finance

a year ago

Esperion Therapeutics: Q3 Earnings Snapshot

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
ESPR

GlobeNewswire

a year ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion to Participate in Upcoming Jefferies London Healthcare Conference
ESPR

GlobeNewswire

a year ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ESPR

Zacks

a year ago

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
ESPR

GlobeNewswire

a year ago

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

Esperion to Report Third Quarter 2024 Financial Results on November 7
ESPR

GlobeNewswire

a year ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings
ESPR

GuruFocus.com

a year ago

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
ESPR

Insider Monkey

a year ago

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
ESPR

GlobeNewswire

a year ago

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ESPR

GlobeNewswire

a year ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
ESPR

Zacks

a year ago

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
ESPR

GlobeNewswire

a year ago

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
ESPR

GlobeNewswire

a year ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
ESPR

GlobeNewswire

a year ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

ESPR

Thomson Reuters StreetEvents

a year ago

Q2 2024 Esperion Therapeutics Inc Earnings Call

ESPR

MT Newswires

a year ago

Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
ESPR

Zacks

a year ago

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
ESPR

Zacks

a year ago

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

Share on Social Networks: